Search results :

Vemurafenib

More information: STITCH, PubChem and possibly Wikipedia

ATC Codes: None found

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3
VIIth nerve paralysis common x x
Rash postmarketing, 0% - 52% x x x
Fatigue postmarketing, 2% - 54% x x x
Gamma-glutamyltransferase increased 0% - 15% x x
Arthralgia postmarketing, 1% - 67% x x x
Photosensitivity reaction postmarketing, 0% - 49% x x x
Dizziness postmarketing, common x x
Erythema nodosum postmarketing, common x x x
Nervous system disorder postmarketing, common x x x
Keratosis pilaris postmarketing, common x x x
Body temperature increased postmarketing, 1% - 19% x x x
Nausea postmarketing, 2% - 43% x x x
Pain in extremity postmarketing, 0% - 18% x x x
Vomiting postmarketing, 1% - 26% x x x
Rash maculo-papular postmarketing, 0% - 21% x x x
Pruritus postmarketing, 0% - 30% x x x
Alopecia postmarketing, 0% - 45% x x x
Asthenia postmarketing, 0% - 11% x x x
Back pain postmarketing, 1% - 11% x x x
Constipation postmarketing, 0% - 24% x x x
Diarrhoea postmarketing, 1% - 29% x x x
Headache postmarketing, 0% - 27% x x x
Seborrhoeic keratosis postmarketing, 0% - 14% x x x
Musculoskeletal pain postmarketing, 0% - 11% x x x
Oedema peripheral postmarketing, 0% - 23% x x x
Myalgia postmarketing, 0% - 24% x x x
Hyperkeratosis postmarketing, 0% - 28% x x x
Decreased appetite postmarketing, 0% - 21% x x x
Anaphylactic shock postmarketing x
Arthritis postmarketing x x x
Basal cell carcinoma postmarketing x x x
Infection postmarketing x x x
Connective tissue disorder postmarketing x x
Cough postmarketing, 0% - 12% x x x
Cyst postmarketing x x x
Dysgeusia postmarketing, 0% - 14% x x x
Eosinophilia postmarketing x x x
Toxic epidermal necrolysis postmarketing, common x x x
Eye disorder postmarketing x x x
Folliculitis postmarketing x x x
Gastrointestinal disorder postmarketing x x
Cardiac disorder postmarketing x x x
Hypersensitivity postmarketing x x x
Hypotension postmarketing x x
Keratoacanthoma postmarketing x x
Keratosis postmarketing x x
Actinic keratosis postmarketing, 0% - 17% x x x
Chronic myelomonocytic leukaemia postmarketing x x x
Mediastinal disorder postmarketing x x x
Malignant melanoma postmarketing x
Neoplasm postmarketing x x x
Neuropathy peripheral postmarketing x x x
Polyp postmarketing x x x
Retinal vein occlusion postmarketing x x x
Stevens-Johnson syndrome postmarketing, common x x x
Erythema postmarketing, 0% - 14% x x
Uveitis postmarketing x x
Angiopathy postmarketing x x x
Vasculitis postmarketing x x x
Common wart postmarketing x x
Weight decreased postmarketing x x
Dry skin postmarketing, 0% - 19% x x x
Malnutrition postmarketing x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing, common x x x
Nerve paralysis postmarketing x
Metastatic melanoma postmarketing x
Skin papilloma postmarketing, 0% - 30% x x x
Photosensitivity postmarketing x x x
Rash generalised postmarketing x
Squamous cell carcinoma of skin postmarketing x x
Infestation NOS postmarketing x x x
Electrocardiogram QT corrected interval prolonged postmarketing x x
Rash papular postmarketing, 0% - 13% x x x
Atrial fibrillation x x
Neoplasm malignant x
Squamous cell carcinoma x
Palmar erythema x
Sunburn postmarketing, 0% - 14% x x x
Hepatotoxicity x
Oropharyngeal squamous cell carcinoma x
Rigors x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

Vemurafenib

Side effects:64
Source:FDA Structured Product Label

Vemurafenib / ZELBORAF

Side effects:70
Source:medicines.org.au

vemurafenib / vemurafenib

Side effects:72
Source:EMA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label